Scarica l'app Stockscreener
18.00
2.33%
0.41
Dopo l'orario di chiusura:
18.22
0.22
+1.22%
Precedente Chiudi:
$17.59
Aprire:
$17.845
Volume 24 ore:
583.14K
Relative Volume:
0.43
Capitalizzazione di mercato:
$1.77B
Reddito:
-
Utile/perdita netta:
$-44.84M
Rapporto P/E:
-38.30
EPS:
-0.47
Flusso di cassa netto:
$-44.23M
1 W Prestazione:
+0.73%
1M Prestazione:
+8.63%
6M Prestazione:
+29.59%
1 anno Prestazione:
+74.42%
Intervallo 1D:
$17.80
$18.17
Intervallo di 1 settimana:
$17.52
$18.61
Portata 52W:
$8.9055
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Confronta SPRY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
18.00 | 1.73B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
ARS Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on assets - jammulinksnews.com
What drives ARS Pharmaceuticals Inc. stock priceTremendous growth opportunities - Autocar Professional
What analysts say about ARS Pharmaceuticals Inc. stockBreakthrough stock performance - jammulinksnews.com
Is ARS Pharmaceuticals Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com
MHRA approves needle-free adrenaline nasal spray for anaphylaxis - Yahoo Finance
EURneffy® (adrenaline nasal spray) Approved in the U.K. as - GlobeNewswire
Revolutionary Needle-Free Alternative to EpiPen Approved in UK: EURneffy Changes Anaphylaxis Treatment - Stock Titan
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? - Yahoo Finance
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' - Yahoo Finance
ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine (SPRY) - Seeking Alpha
(SPRY) Technical Data - news.stocktradersdaily.com
ARS Pharmaceuticals: 'Betting On The Come' (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals: Insider Liquidity vs. Institutional Buying – A Contrarian Opportunity? - AInvest
ARS Pharmaceuticals: Navigating Insider Sales Amid Growth Catalysts - AInvest
Raymond James reiterates strong buy on ARS Pharmaceuticals stock - Investing.com India
ARS Pharmaceuticals (SPRY) Soars 4.48% on Earnings, Partnership - AInvest
ARS Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
High Growth Tech Stocks in US for June 2025 - simplywall.st
Ars pharma CCO Karas sells $240k in SPRY stock - Investing.com
Learn to Evaluate (SPRY) using the Charts - news.stocktradersdaily.com
ARS Pharmaceuticals | 6/18/25 - ktnv.com
FDA Reviewing Oral Epinephrine Film for Possible Approval - Allergic Living
Asthma Market to Expand Significantly by 2034, States - openPR.com
Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Insider Monkey
Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey
ARS Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily
Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com
Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals - WBFF
Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
BNP Paribas Financial Markets Purchases New Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ProShare Advisors LLC Buys 3,436 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $354,000 Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ars Pharmaceuticals Inc Azioni (SPRY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Karas Eric | Chief Commercial Officer |
Jul 01 '25 |
Sale |
16.99 |
15,000 |
254,860 |
10,315 |
| Flynn James E | 10% Owner |
Jun 27 '25 |
Sale |
18.46 |
740,149 |
13,663,151 |
4,887,254 |
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):